Pegfilgrastim Dosing (per Label)
ورودیهای بالینی بیمار
حداقل ۲ — حداکثر ۲۰۰ • واحد: kg
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Dosed≥ 0
The Pegfilgrastim Dosing (per Label) calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include patient type. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Pegfilgrastim (Neulasta) dosing per FDA label: adults 6 mg SC once per chemotherapy cycle, ≥24 hours after cytotoxic chemotherapy and ≥14 days before the next cycle. Pediatric weight bands: <10 kg 0.1 mg/kg, 10-20 kg 1.5 mg, 21-30 kg 2.5 mg, 31-44 kg 4 mg, ≥45 kg 6 mg.
Clinical Indication
The Pegfilgrastim Dosing (per Label) is indicated for bedside clinical practice to support Pegfilgrastim (Neulasta) dosing per FDA label: adults 6 mg SC once per chemotherapy cycle, ≥24 hours after cytotoxic chemotherapy and ≥14 days before the next cycle. Pediatric weight bands: <10 kg 0.1 mg/kg, 10-20 kg 1.5 mg, 21-30 kg 2.5 mg, 31-44 kg 4 mg, ≥45 kg 6 mg.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
Adult: fixed 6 mg. Pediatric: weight-band dosing per label.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| patient_type | string | Yes | Patient type |
| weight_kg | float | No | Weight (pediatric only, kg)(kg) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| ≥ 0 | Dosed | Pegfilgrastim dose |
Evidence-Based References (EBM)
- Neulasta (pegfilgrastim) FDA Prescribing Information. Amgen Inc. Dosage: 6 mg subcutaneously once per chemotherapy cycle; pediatric weight-based dosing as labeled.